Eton Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | $21.8M | $39.0K | $959.0K |
| Cost of Revenue | $37.2M | $15.6M | $10.6M | $6.9M | $2.8M | $436.0K | $453.0K |
| Gross Profit | $42.7M | $23.4M | $21.1M | $14.3M | $19.0M | $-397.0K | $506.0K |
| Gross Margin | 53.5% | 60.0% | 66.6% | 67.4% | 87.1% | -1,017.9% | 52.8% |
| Operating Expenses | |||||||
| Research & Development | $7.8M | $3.3M | $3.3M | $4.0M | $6.2M | $14.1M | $11.6M |
| SG&A Expense | $35.8M | $22.8M | $18.9M | $18.6M | $14.3M | $12.6M | $7.6M |
| Operating Income | $-844.0K | $-2.6M | $-1.2M | $-8.3M | $-1.5M | $-27.1M | $-18.6M |
| Operating Margin | -1.1% | -6.7% | -3.8% | -38.9% | -6.8% | -69,515.4% | -1,939.6% |
| Interest Expense | $4.8M | $2.0M | $1.1M | $955.0K | $1.0M | $884.0K | $98.0K |
| Pretax Income | $-4.6M | $-3.8M | $-689.0K | $-9.0M | $-2.0M | $-28.0M | $-18.3M |
| Income Tax Expense | $43.0K | $15.0K | $247.0K | $0 | $0 | — | — |
| Net Income | $-4.6M | $-3.8M | $-936.0K | $-9.0M | $-2.0M | $-28.0M | $-18.3M |
| Net Margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | -71,717.9% | -1,910.3% |
| EPS (Basic) | $-0.17 | $-0.15 | $-0.04 | $-0.36 | $-0.08 | $-1.33 | $-1.03 |
| EPS (Diluted) | — | — | — | — | $-0.08 | $-1.33 | $-1.03 |
| Shares Outstanding (Basic) | 26.9M | 25.9M | 25.6M | 25.1M | 25.2M | 21.0M | 17.9M |
| Shares Outstanding (Diluted) | 26.9M | 25.9M | 25.6M | 25.1M | 25.2M | 21.0M | 17.9M |
| Dividends Per Share | — | — | — | — | — | — | — |